Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma

Inclusion Criteria: 1. Histological diagnosis of glioblastoma multiforme. 2. Radiological progression on an MRI scan, according to the RANO criteria, in the context of a known glioblastoma multiforme, already treated with the Stupp protocol of combined radiotherapy-Temozolomide. This implies a measurable disease on MRI. 3. Prior radiotherapy and temozolomide, as per the Stupp protocol, no sooner than 4 weeks, is permitted. 4. Eighteen or more years of age. 5. Performance status: Karnofsky ranging from 60 to 100%. 6. Haematopoietic parameters at recruitment: * Platelet counts \> 100,000/mm3. * Hemoglobin \> 8 g/dL. * Absolute neutrophil count \> 1,500/mm3. 7. No impaired bone marrow function. 8. Hepatic parameters at recruitment: * Bilirubin ≤ 2 times normal value. * AST and ALT ≤ 2 times upper limit of normal (ULN). * Alkaline phosphatase ≤ 2 times ULN (unless attributed to the tumour). * No impaired hepatic function. 9. Renal parameters at recruitment: * No impaired renal function. * Creatinine no greater than 1.5 fold of the normal value. * Creatinine clearance \> 30 ml/min. 10. Normal ECG. 11. Written informed consent obtained. * Patients should be either sterile or else use a contraceptive strategy (for at least 2 months prior to study accruals). Exclusion Criteria: 1. Presence of a severe psychiatric or medical condition that would interfere with treatment administration or study recruitment. 2. Presence of an active autoimmune disease. 3. No prior cardiac disease within the past 5 years OR LVEF of at least 50% at baseline ultrasound. 4. Occurrence of another malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or in situ cervical carcinoma. 5. Pregnancy (as confirmed by a positive b-HCG) or actively nursing. 6. Presence of an uncontrolled systemic infection.